Clinical trials to study FcRn blockade have been initiated for various conditions such as immune thrombocytopenia (ITP-phase 2 trial) [10, 11], generalised myasthenia gravis (MG-phase 2 trials [12, 13], MG-phase 3 trials [14, 15]) and CIDP. Here, FCGRT is linked to autoimmune thrombocytopenic purpura.